30
Participants
Start Date
January 30, 2024
Primary Completion Date
June 1, 2027
Study Completion Date
August 1, 2027
Tucatinib
taken orally
Eribulin
taknen intravenously
Trastuzumab
taken intravenously
RECRUITING
George Washington Medical Faculty Associates, Washington D.C.
RECRUITING
University of Wisconsin Carbone Cancer Center, Madison
RECRUITING
University of Colorado, Aurora
RECRUITING
New Mexico Cancer Care Alliance, Albuquerque
RECRUITING
Swedish Cancer Institute, Issaquah
RECRUITING
Cancer Care Northwest, Spokane Valley
Lead Sponsor
Criterium, Inc.
INDUSTRY